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Abstract
Background:  Staphylococcus aureus, one of the most frequently isolated pathogens in both
hospitals and the community, has been particularly efficient at developing resistance to
antimicrobial agents. In developed countries, as methicillin-resistant S. aureus (MRSA) has prevailed
and, furthermore, as S. aureus with reduced susceptibility to vancomycin has emerged, the
therapeutic options for the treatment of S. aureus infections have become limited. In developing
countries and especially African countries very little is known concerning the resistance of S. aureus
to antibiotics. In Madagascar no data exist concerning this resistance.
Objective: To update the current status of antibiotic resistance of S. aureus in Antananarivo,
Madagascar.
Methods:  Clinical  S. aureus isolates were collected from patients at the Institut Pasteur of
Madagascar from January 2001 to December 2005. Susceptibility tests with 18 antibiotics were
performed by the disk diffusion method.
Results: Among a total of 574 isolates, 506 were from community-acquired infections and 68 from
nosocomial infections. There was no significant difference in the methicillin resistance rate between
community-acquired strains (33 of 506; 6.5%) and nosocomial strains (3 of 68, 4.4%). Many MRSA
isolates were resistant to multiple classes of antibiotics. Resistance to tetracyclin, trimethoprim-
sulfamethoxazole and erythromycin was more common. Among MRSA isolates resistance rates to
rifampicin, fusidic acid, gentamicin and ciprofloxacin were lower than that observed with other
drugs easily available in Madagascar. No isolates were resistant to glycopeptides.
Conclusion:  The rate of methicillin-resistant  S. aureus is not different between community-
acquired and nosocomial infections and is still rather low in Madagascar.
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Background
Staphylococcus aureus is an important cause of serious
infections in both hospitals and the community. S. aureus
has been found to be the most frequently isolated patho-
gen causing bloodstream infections, skin and soft tissue
infections, and pneumonia [1-3]. Unfortunately this path-
ogen has been particularly efficient at developing resist-
ance to antimicrobial agents. Since the first isolation of
methicillin-resistant S. aureus (MRSA) in the United King-
dom in 1961 [4], increasing rates of methicillin resistance
among S. aureus strains have been a cause for concern,
especially in developed countries. In addition, MRSA has
become resistant to multiple other antimicrobial agents.
Until recently, vancomycin was believed to have retained
activity against all strains of S. aureus; therefore, the spread
of MRSA has led to increased vancomycin usage and
hence increased selective pressure for the development of
resistance [5]. In developing countries, since vancomycin
is hardly available due to its cost, resistance to this drug is
not yet a problem. Resistance to elder and/or cheaper anti-
biotics such as macrolide-lincosamide-streptogramin,
rifampin, ciprofloxacin, fusidic acid and trimethoprim-
sulfamethoxazole is more important.
Data concerning resistance of S. aureus to antibiotics in
Madagascar are rare. A previous study was conducted in
1997–1998 by the Institut Pasteur of Madagascar (IPM)
on 231 community-acquired strains [6]. In this study, no
strain was resistant to methicillin. Another study con-
cerned only 35 strains isolated from urinary tract infec-
tions from January 2004 and April 2006 [7]. Some of
these strains are included in the present study. Only 2
strains (8%) were resistant to methicillin.
The aim of the present study was to make an update on
the susceptibility of S. aureus isolates from the IPM to var-
ious drugs and therefore to improve the empirical
approaches to the therapy of serious infections.
Materials and methods
Bacterial isolates
Clinical S. aureus isolates were collected from patients pre-
senting at IPM for various bacteriological exams or from
samples taken from hospitalized patients and sent at IPM,
from January 2001 to December 2005. Only one isolate
per patient was included in the study. Criteria for nosoco-
mial infection were all infections developed in a patient
after 48 hours of hospitalization. Strains were considered
as community-acquired when isolated from patients that
have not been hospitalized recently or from patients
before 48 hours of hospitalization. Initial identification
was based on colony morphology, gram staining, catalase
and agglutination tests with Pastorex Staph (Biorad,
Marne la Coquette, France). All isolates were immediately
stored at -70°C.
Antibiotic susceptibility testing
Susceptibility to antibiotics was assessed by the disk diffu-
sion technique on Mueller-Hinton agar. An inoculum of
106 CFU/ml was prepared as recommended by the Antibi-
ogram Committee of the French Microbiology Society
(CASFM) [8]. After 24 h at 37°C, the zone of inhibition
was measured. For susceptibility to oxacillin, an inoculum
of 107 CFU/ml was prepared and the plate was incubated
at 37°C for 24 hours on Mueller-Hinton agar + 2% NaCl.
Antibiotic disks were obtained from Biorad, Marne la
Coquette, France.
The following 18 antibiotics were tested: oxacillin, peni-
cillin, erythromycin, lincomycin, pristinamycin, vanco-
mycin, teicoplanin, ciprofloxacin, tetracycline,
minocycline, trimethoprim-sulfamethoxazole,
rifampicin, fusidic acid, gentamicin, kanamycin, tobramy-
cin, chloramphenicol and fosfomycin. The breakpoints
for resistance were those recommended by the CASFM [8].
S. aureus ATCC 25923 was used as control.
The resistance rate was calculated as the number of non-
susceptible isolates divided by the total number of iso-
lates. Multidrug resistance was defined as resistance to
penicillin and oxacillin plus three or more of the follow-
ing agents: erythromycin, lincomycin, rifampin, cipro-
floxacin, gentamicin, tetracycline, and trimethoprim-
sulfamethoxazole.
Comparison of resistance rate between nosocomial or
community-acquired strains and between MRSA and
MSSA was based on Chi square test of Pearson or exact test
of Fisher according to the distribution; p significant level
considered was p < 0.05.
Results
A total of 574 isolates from 506(88.2%) community-
acquired and 68 (11.8%) nosocomial infections, exclud-
ing consecutive samples from the same patient, were col-
lected. Strains were isolated from 367 females and 207
males (mean age. 34.4 years old 95%CI [32.9–35.9],
range 1 month – 90 years old, sex-ratio M/F: 0.56). Con-
cerning the origin of the community-acquired isolates,
212 (41.9%) were from genital tract infections, 177
(36.0%) from pus, 97 (19.2%) from urinary tract infec-
tions and 20 (4.0%) were from the respiratory tract infec-
tions. For nosocomial strains, most (38) were isolated
from surgical wounds (55.2%), 15 from cutaneous pus
(22.4%) and 15 from hemoculture (22.4%).
Overall, the prevalence of MRSA was 6.5% (33 of 506 iso-
lates) for community-acquired strains, and 4.4% (3 of 68)
for nosocomial infections (p = 0.5). Rates of resistance of
methicillin-sensitive S. aureus (MSSA) and MRSA to the
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(22.2%) MRSA isolates were multidrug resistant (Table
2).
Of the 74 MSSA and 7 MRSA isolates that were resistant to
erythromycin, respectively 26 (35.1%) and 7 (100%) had
the constitutive macrolide-lincosamide-streptogramin B
(MLSB) resistance phenotype. Of the 7 MRSA, 2 (28.6%)
had also the streptogramin A (MLSA) resistance pheno-
type.
Susceptibility for minocyclin was available for 239
(74.4%) tetracyclin resistant strains, only 82 (34.3%)
were also resistant to minocyclin.
Of the 574 isolates, 47 (8.2%) were resistant to at least
one of the three aminoglycosides tested. Resistance of the
MRSA isolates to aminoglycosids was less than expected:
24.1% were resistant to kanamycin, 17.2% to tobramycin,
and only 10.3% to gentamicin.
Resistance rate to minocyclin was significantly higher in
community-acquired than in nosocomial infection. No
significant difference was observed in other antibiotics
(Table 3),
There were no significant differences in the resistance rates
to any antibiotic according to the site of infection, the age
group or the year of isolation of the strains (data not
shown).
Discussion
Our study presented some limits. Indeed, probably not all
strains in our study were responsible for infections since
241 strains were isolated from genital infections using
swabs and these strains are often contaminants. Concern-
ing the detection of methicillin resistance we have fol-
lowed the guidelines of the French Committee for the
Antibiogram which recommend to use oxacillin on MH +
2% NACL or cefoxitin on MH (which seems more reliable
[9]), with incubation at 37°C [8]. The Clinical and Labo-
ratory Standards Institute recommend incubation at 35°C
[10]. Some recent articles show that indeed 35°C seems to
be more reliable[9]. However we have tested in 2005
more than 100 strains using both oxacillin on MH + 2%
NACL and cefoxitin and did not find any discrepancy.
Using cefoxitin at 37°C, detection of methicillin resist-
ance could be overestimated and the discrepancy using
strains presenting a low level of resistance is not impor-
tant [9]. In our study most of the strains are fully sensitive
to nearly all antibiotics, therefore discrepancies are likely
to be very rare and thus the rate of methicillin resistance
presented in our study is likely to be very close to the real-
ity.
The prevalence of MRSA has increased worldwide, as it is
evident from many surveillance studies [2,3,11]. How-
ever, there are considerable differences between countries.
The very highest rates of methicillin resistance among S.
aureus isolates have been noted in developed countries
and especially in Western Pacific Regions, both in com-
munity acquired and nosocomial infections [11]. Usually,
the prevalence of MRSA is lower in developing countries
Table 1: Antibiotic resistance profiles of 538 MSSA and 36 MRSA isolates from patients presenting at the Pasteur Institute of 
Madagascar, as determined by disk diffusion.
MSSA MRSA
Number of isolates that were Number of isolates that were P
S I or R Resistance rate (%) S I or R Resistance rate (%)
Penicillin 66 472 87.7 0 36 100 0.11
Erythromycin 469 69 12.8 24 12 33.3 <0.01
Lincomycin 509 29 5.4 29 7 19.4 <0.01
Pristinamycin 538 0 0.0 34 2 2.0 -
Kanamycin 505 33 6.13 26 10 27.8 <0.01
Tobramycin 521 17 3.2 27 9 25.0 <0.01
Gentamicin 532 6 1.12 32 4 11.1 <0.01
Ciprofloxacin 509 29 5.4 31 5 13.9 0.03
Tetracyclin 244 294 54.6 9 27 75.0 0.01
Minocyclin 466 72 13.4 26 10 27.8 0.01
Trimethoprim-sulfamethoxazole 458 80 14.9 22 14 38.9 <0.01
Rifampicin 517 21 3.9 31 5 13.9 0.01
Fusidic acid 493 45 8.4 29 7 19.4 0.02
Chloramphenicol 487 51 9.5 28 8 22.2 0.01
Fosfomycin 530 8 1.5 35 1 2.8 NS
Vancomycin 538 0 0.0 36 0 0.0 -
Teicoplanin 538 0 0.0 36 0 0.0 -Annals of Clinical Microbiology and Antimicrobials 2007, 6:5 http://www.ann-clinmicrob.com/content/6/1/5
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as in Africa. In our study, resistance to methicillin (5.8%)
is rather low. In other studies conducted in African hospi-
tals, resistance to methicillin varied from 21 to 63% in
South Africa, and from 21 to 31% in Cameroon, Nigeria,
Kenya, Ivory-Coast and Ethiopia [12]. In contrast, in
North Africa, it was less than 10% in Tunisia and Algeria
[12]. Although rather low, the rate of resistance to methi-
cillin has increased between 1997–1998 [6] and our study
from 0 to 5.8%. In contrast, the overall resistance to other
drugs has not increased.
In contrast to other studies, where resistance rates are
higher in nosocomial infections [11], we did not find any
significant difference in the rates of resistance to most of
antibiotic between strains isolated from nosocomial or
community-acquired infections. Of course the number of
nosocomial strains in our study is rather low, since IPM is
not located in a hospital and mostly realise tests for out-
patients. Nevertheless it is very likely that this reflects the
reality of the resistance rates in the hospitals of Antanan-
arivo. Although curious, this may be explained by the fact
that the antibiotics delivered at the hospitals are the same
that those found at the chemist's and often, inpatients
have to buy the medicines outside the hospital.
About one third of the MRSA isolates were resistant to
multiple other antimicrobial agents, as previously noted
in the literature. In general, elevated rates of multidrug
resistance may emerge from diverse isolates of S. aureus
under antimicrobial pressure or as a result of widespread
person-to-person transmission of multidrug-resistant iso-
lates [13]. The fact that only a few antibiotics are easily
available in Madagascar, may explain why resistance to
major drugs used in developed countries is not frequent in
Table 3: Antibiotic resistance profiles of 506 Community acquired and 68 Nosocomial isolates, as determined by disk diffusion.
Community acquired Nosocomial infection
Resistance rate (%) Resistance rate (%) P
Penicillin 87.9 91.2 0.43
Oxacillin 6.5 4.4 0.50
Erythromycin 14.6 10.3 0.43
Lincomycin 6.1 7.3 0.51
Pristinamycin 0.4 0.0 0.56
Kanamycin 7.3 8.8 0.65
Tobramycin 4.5 4.4 0.96
Gentamicin 1.9 0 -
Ciprofloxacin 5.5 8.8 0.30
Tetracyclin 56.5 51.4 0.43
Minocyclin 15.8 2.9 <0.01
Trimethoprim sulfamethoxazole 16.8 13.2 0.44
Rifampicin 4.1 7.3 0.25
Fusidic acid 8.9 10.3 0.70
Chloramphenicol 10.1 11.7 0.66
Fosfomycin 1.6 1.5 0.94
Vancomycin 0 0 -
Teicoplanin 0 0 -
Multiresistant 1.58 0 -
Table 2: Phenotypic resistance patterns of 8 multiresistant S. aureus isolates for eleven antibiotics
KAN TOB GEN TCY MNO ERY LIN PRI CIP SXT RIF
SSSRSRRSSRS
SSSRRRRSSSS
RSSRSRRSRRS
RRRRRSSSSRS
SSSRRRRRRRI
RRRRRRSSSRS
SSSRSSSSRSR
RRRRRRRRRRI
KAN: kanamycin, TOB: tobramycin, GEN: gentamycin, TCY: tetracycline, MNO:minocyclin, ERY: erythromycin, LIN: lincomycin, PRI: 
pristiniamycin, CIP: ciprofloxacin, SXT: Trimethoprim-sulfamethoxazole, RIF: rifampycinPublish with BioMed Central    and   every 
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our study. Although resistance rates to other antibiotics is
usually significantly higher than in MSSA, the rates are
much lower than in most studies. In contrast, resistance
rates to cheaper antibiotics such as tetracyclin and trime-
toprim-sulfamethoxazole are higher than those observed
in developed countries and are similar to that observed in
African countries [11,12,14].
Apart from glycopeptides which remain the most efficient
on MRSA strains, the rates of resistance of MRSA to pristi-
namycin (0.4%), rifampicin (10.3%), ciprofloxacin
(10.3%) and gentamicin (10.3%), were much lower than
those to other antibiotics. In Madagascar ciprofloxacin,
trimethoprim-sulfamethoxazole, tetracyclin and erythro-
mycin are the only widely available oral agents.
Rifampicin is only used for tuberculosis treatment.
Because of their low price and the low rate of resistance,
ciprofloxacin or rifampicin in combination with gen-
tamicin may be the more suitable treatment on MRSA
strains.
In summary, the rate of methicillin resistance among S.
aureus isolated at the Institut Pasteur de Madagascar, both
from community-acquired and nosocomial infections,
remains rather low compared to developed countries and
many developing countries in Africa. This is important for
Malagasy physicians since the preferred regimen for sus-
pected staphylococcal infections are cloxacillin or amoxi-
cillin plus clavulanic acid. However a nationwide survey
should be undertaken to confirm these results and could
be valuable for the selection of therapeutic alternatives.
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